Suprax (cefixime tablets, from Lupin) 400mg has been made available again for the treatment of susceptible bacterial infections, including Neisseria gonorrhoeae.
Relistor (methylnaltrexone bromide for SC injection, from Progenics and Wyeth) has been approved for the treatment of opioid-induced constipation (OIC) in palliative care patients with advanced illness, when response to laxative therapy has been insufficient.
The FDA has approved a once-monthly dose of Actonel (risedronate sodium tablets, from Procter & Gamble and sanofi-aventis) for the treatment and prevention of postmenopausal osteoporosis.
The FDA has approved the use of Vyvanse (lisdexamfetamine dimesylate capsules, from Shire) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults.
Aplenzin (bupropion hydrobromide extended-release tablets, from Biovail) has been approved by the FDA for the treatment of depression in adults.
Cimzia (certolizumab pegol injection, from UCB) has been approved by the FDA for the treatment of moderate-to-severe Crohn’s disease (CD) when conventional therapies have failed.
GlaxoSmithKline has expanded its Tums product line with the introduction of Tums QuikPak (calcium carbonate), an instant dissolve antacid powder packet for the treatment of heartburn.
La Roche-Posay’s Anthelios 40 sunscreen, formulated with Mexoryl SX, has received FDA approval for UVA and UVB protection.
Omnaris (ciclesonide nasal spray, from Sepracor) is now available for the treatment of nasal symptoms associated with seasonal allergic rhinitis in patients ≥6 years of age and for perennial allergic rhinitis in patients ≥12 years of age.
The FDA has approved Patanase (olopatadine hydrochloride nasal spray, from Alcon) for the relief of seasonal allergic rhinitis in patients ≥12 years of age.